Changchun Deng, MD, PHD
Dr. Deng is an Assistant Professor of Clinical Medicine and Experimental Therapeutics at Columbia University Medical Center.
Dr. Deng attained his M.D. from Suzhou Medical College, China, and then earned his Ph.D. degree in Molecular, Cellular, and Developmental Biology from the University of Pittsburgh. Following his Ph.D. training he completed a post-doctoral research fellowship in Radiation and Cancer Biology at Stanford University. He then went on to complete a residency in Internal Medicine at the Lincoln Medical Center at Weill Cornell Medical College. Following his residency, he performed his Fellowship in Hematology and Oncology at the University of Texas Southwestern Medical Center, and New York Presbyterian Hospital /Columbia University Medical Center. After his fellowship training, Dr. Deng was appointed to the faculty at the New York University School of Medicine. Most recently, Dr. Deng was appointed Assistant Professor of Clinical Medicine and Experimental Therapeutics at the New York Presbyterian Hospital/Columbia University Medical Center.
Dr. Deng is board certified in Internal Medicine, Medical Oncology, and Hematology. He has well-rounded training in all aspects of Internal Medicine, and has substantial expertise in the management of hematological malignancies. Dr. Deng has published on the treatment of mantle cell lymphoma and T- cell lymphoma. He is currently the Principle Investigator (PI) of several promising clinical trials with the aim to develop novel and more effective treatments for patients with lymphoid malignancies.
In addition to patient care and clinical research, Dr. Deng is also conducting detailed studies into the pathogenesis of lymphoma and the discovery and development of new drugs for the treatment of lymphoma. His research has resulted in publications in high impact scientific journals, and presentations at national meetings. Recently, he has focused on understanding the mechanistic basis underlying the sensitivity of lymphoma cells to novel epigenetic based treatments. Knowledge from his work will form the basis to potentially provide personalized lymphoma care based on the unique epigenetic signature of an individual patients’ lymphoma.